Cytosorbents (CTSO) vs Picard Medical (PMI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cytosorbents (CTSO) has outperformed Picard Medical (PMI) over the past year, losing 70.6% versus a loss of 94.0%. Picard Medical is the larger company by market cap ($18.1 million vs $13.1 million), about 1.4 times the size. Cytosorbents converts more of its revenue into profit, with a net margin of -22.1% versus -546.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTSO | PMI |
|---|---|---|
| Share price | $4.16 | $6.79 |
| Market cap | $13.12M | $18.07M |
| 1-day change | -18.91% | +7.78% |
| YTD return | -67.45% | -92.24% |
| 1-year return | -70.58% | -94.02% |
| 5-year return | -95.62% | — |
| P/E ratio (TTM) | — | 3.04 |
| EPS (TTM) | $-5.62 | $2.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $37.06M | $4.94M |
| Revenue growth (YoY) | +4.12% | +12.50% |
| Net income (latest FY) | $-8.20M | $-27.00M |
| Gross margin | 71.48% | -4.13% |
| Operating margin | -39.79% | -268.36% |
| Net margin | -22.12% | -546.60% |
| 52-week high | $17.00 | $208.00 |
| 52-week low | $2.84 | $2.65 |
| Distance from 52-week high | -75.53% | -96.74% |
| Analyst consensus | none | — |
| Avg. price target upside | +1041.83% | — |
| Average volume | 37.34K | 1.45M |
| Shares outstanding | 3.15M | 2.66M |
| Employees | 129 | 75 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTSO has outperformed PMI by 23.4 percentage points over the past year.
- Cytosorbents is more profitable, keeping -22.1 cents of every revenue dollar as net income versus -546.6 cents for Picard Medical.
- Picard Medical grew revenue faster in its latest fiscal year (+12.50% vs +4.12%).
About Cytosorbents
CTSO stock →Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications.
Health Care · Medical/Dental Instruments · 129 employees
About Picard Medical
PMI stock →Picard Medical, Inc., together with its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure.
Health Care · Medical/Dental Instruments · 75 employees
CTSO vs PMI FAQ
Which is bigger, Cytosorbents or Picard Medical?
Picard Medical (PMI) is larger, with a market capitalization of $18.07M compared with $13.12M for Cytosorbents (CTSO).
Which stock has performed better over the past year, CTSO or PMI?
CTSO returned -70.58% over the past 12 months, compared with -94.02% for PMI (price return, excluding dividends). Past performance does not predict future results.
Are Cytosorbents and Picard Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.